HEALEY ALS Platform Trial

https://www.massgeneral.org/neurology/als/research/platform-trial

Healey Center
Sean M. Healey & AMG Center for ALS at Mass General
Traditional Clinical Trial
Vs.
HEALEY ALS Platform Trial

Cuts time in 1/2
Cuts costs by 1/3
Reduces placebo

"I lost the privilege of working on the human time clock on January 6, 2018. The ALS clock is a lot faster" 

Sandy – Person with ALS
Platform trials may possibly be the best thing I have seen since diagnosis!

Working with the entire ALS Community to launch the trial rapidly and efficiently

ALS Platform Trial
Industry Workshop

“Platform trials may possibly be the best thing I have seen since diagnosis!”

54 TRIAL-READY SITES
1 Central IRB

FDA
INDUSTRY
PATIENTS
FOUNDATIONS
SITES/INVESTIGATORS
The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial

Regimen A
(n=160 for each regimen)

Regimen B

Regimen C

Regimen D

3:1 Randomization within each Regimen

Zilucoplan
Placebo

Verdiperstat
Placebo

CNM-Au8
Placebo

Pridopidine
Placebo

Shared Placebo

Screening

Regimen Assignment

Open Label Extension

Open Label Extension

Open Label Extension

Open Label Extension

24 weeks on study drug (active:placebo = 3:1)
LEADERSHIP & TRAINING

RGA Regimen Leads
- Sabrina Paganoni, MGH, Regimen Lead
- Christina Fournier, Emory, Regimen co-Lead
- Senda Ajroud-Driss, Northwestern, Regimen Steering Committee Member

RGB Regimen Leads
- Jinsy Andrews, Columbia, Regimen Lead
- Suma Babu, MGH, Regimen co-PI
- Eufrosina Young, MD, SUNY Upstate, Regimen Steering Committee Member

RGC Regimen Leads
- James Berry, MGH, Regimen co-Lead
- Nicholas Maragakis, Johns Hopkins, Regimen co-Lead
- Elijah W. Stommel, MD, Hickcock, Regimen Steering Committee Member

RGD Regimen Leads
- Jeremy Shefner, Barrow Neurological Institute, Regimen Lead
- Bjorn Oskarsson, Mayo Clinic, Regimen co-Lead
- Katie Nicholson, MGH, Regimen Steering Committee Member
Exploratory Endpoints

- DNA
- Neurofilaments
- Biomarkers (Blood, Urine, CSF)
- Speech Analysis
- Home Spirometry

Endpoint Development Engine
## ENROLLMENT UPDATES

As of 9/16/2021

<table>
<thead>
<tr>
<th>Description</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total # Consented Master Protocol</td>
<td>746</td>
</tr>
<tr>
<td>Total # Assigned to Regimen</td>
<td>590</td>
</tr>
<tr>
<td>Total # Randomized within Regimen</td>
<td>529</td>
</tr>
<tr>
<td>RGA Total # Randomized</td>
<td>147</td>
</tr>
<tr>
<td>RGB Total # Randomized</td>
<td>160</td>
</tr>
<tr>
<td>RGC Total # Randomized</td>
<td>160</td>
</tr>
<tr>
<td>RGD Total # Randomized</td>
<td>69</td>
</tr>
<tr>
<td>Total # OLE Initiation</td>
<td>200</td>
</tr>
</tbody>
</table>

Enrollment complete for RGB & RBC

“I’m looking forward to helping find a cure for ALS.”
- Platform trial participant
Trial Updates

- Adding 21 Expansion Sites
- Regimen E (5th) – Seelos
  - 2021 Q3 Start-up
  - 2021 Q4 Enrolling
- 6th Revalesio in design/discussion
- Three more selected and pending contract
- Interim Analysis
  - Began Q2 2021 and every 3 months
Therapy Evaluation Committee
3 NEW applications reviewed in August 2021

➢ 60 Companies Interested

➢ 33 Applied & Reviewed

Committee Recommendations:

➢ 9 Selected - A. Immediate-ready for inclusion in platform trial
   (6 Contracted; 3 Pending Contract)

➢ 13 - B. Future-to be considered once additional data is obtained (10 launching trial in ALS outside of platform trial)

➢ 11 - C. Should not be considered for this platform trial (2 launching trial in ALS outside of platform trial)
LEADING INNOVATION THROUGH
MULTI CENTER EXPANDED ACCESS PROGRAM
COMPANION TO HEALEY ALS PLATFORM TRIAL

➢ Provide access to experimental treatments useful data on safety and biomarkers

➢ For participants ineligible for platform trial

➢ Three EAPs underway!
   1. **Biohaven EAP** 35 Participants at 3 centers
   2. **Clene EAP** 15 Participants at 3 centers
   3. **Prilenia EAP** 24 Participants at 3 centers
2021 ALS SCHOLARS IN THERAPEUTICS
JULY 1, 2021 – JUNE 30, 2023

➢ 21 global applicants
➢ 6 countries represented (Australia, Canada, China, England, Switzerland, United States)

Brian Jude Joseph, PhD
Harvard University
Developing U1-inhibition as a treatment modality for SOD1 ALS

Matthew Anthony White, PhD
Kings College London
Targeting TDP-43 Autoregulation for Therapeutic Benefit in ALS-FTD

Juliet Goldsmith, PhD
University of Pennsylvania
Autophagic regulation of mitochondrial DNA in ALS

Su Min Lim, PhD
Massachusetts General Hospital/Harvard Medical School
Multiplexed Image-based Platform for Therapeutic Development in ALS